Author: admin

  • Posted in Publications
  • Comments Off on [Journal of Obstetrics & Gynecology] Return of spontaneous menses and fertility after removal of the Liletta™ levonorgestrel intrauterine system

Medicines360, a global nonprofit pharmaceutical company, today announced an agreement with Marie Stopes International (MSI), a global nonprofit family planning organization, to expand access to Medicines360’s hormonal intrauterine device, LNG IUS (levonorgestrel-releasing intrauterine system, 52mg), bringing further contraceptive options to the women of Kenya.

  • Posted in Press Releases
  • Comments Off on Medicines360 Announces New Partnership With Marie Stopes International To Expand Access To Its Hormonal IUD To Women In Kenya, East Africa
  • Posted in Publications
  • Comments Off on [Contraception] Assessment of expulsions in nulliparous and multiparous women during the first year of use of Liletta™, a new 52 mg levonorgestrel-releasing intrauterine system
  • Posted in Publications
  • Comments Off on [Contraception] Amenorrhea rates during the first year of use of Liletta™, a new 52 mg levonorgestrel-releasing intrauterine system

Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the company has appointed Jessica Grossman, M.D., as its Chief Executive Officer, effective immediately. Dr. Grossman has been chair of the Board of Directors of Alliance Partners360, Medicines360’s for-profit subsidiary, since 2014 and a director of Medicines360 since 2011.

  • Posted in Press Releases
  • Comments Off on Medicines360 Names Jessica Grossman as CEO
  • Posted in Publications
  • Comments Off on [Contraception] Three year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system